Abstract

Inflammatory bowel disease (IBD) is a lifelong inflammatory disorder with relapsing–remission cycles, which is currently diagnosed by clinical symptoms and signs, along with laboratory and imaging findings. However, such clinical findings are not parallel to the disease activity of IBD and are difficult to use in treatment monitoring. Therefore, non-invasive quantitative imaging tools are required for the multiple follow-up exams of IBD patients in order to monitor the disease activity and determine treatment regimens. In this study, we evaluated a dual P- and E-selectin-targeted microbubble (MBSelectin) in an interleukin-2 receptor α deficient (IL-2Rα−/−) spontaneous chronic IBD mouse model for assessing long-term anti-inflammatory effects with ultrasound molecular imaging (USMI). We used IL-2Rα−/− (male and female on a C57BL/6 genetic background; n = 39) and C57BL/6 wild-type (negative control; n = 6) mice for the study. USMI of the proximal, middle, and distal colon was performed with MBSelectin using a small animal scanner (Vevo 2100) up to six times in each IL-2Rα−/− mouse between 6–30 weeks of age. USMI signals were compared between IL-2Rα−/− vs. wild-type mice, and sexes in three colonic locations. Imaged colon segments were analyzed ex vivo for inflammatory changes on H&E-stained sections and for selectin expression by immunofluorescence staining. We successfully detected spontaneous chronic colitis in IL-2Rα−/− mice between 6–30 weeks (onset at 6–14 weeks) compared to wild-type mice. Both male and female IL-2Rα−/− mice were equally (p = 0.996) affected with the disease, and there was no significant (p > 0.05) difference in USMI signals of colitis between the proximal, middle, and distal colon. We observed the fluctuating USMI signals in IL-2Rα−/− mice between 6–30 weeks, which might suggest a resemblance of the remission-flare pattern of human IBD. The ex vivo H&E and immunostaining further confirmed the inflammatory changes, and the high expression of P- and E-selectin in the colon. The results of this study highlight the IL-2Rα−/− mice as a chronic colitis model and are suitable for the long-term assessment of treatment response using a dual P- and E-selectin-targeted USMI.

Highlights

  • Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract.IBD comprises two distinct phenotypes: Crohn’s disease (CD), and ulcerative colitis (UC).The prevalence of IBD has been increasing during past decades, from developed to developing countries, especially in pediatric patients [1,2]

  • This study shows that IL-2Rα-/- mice develop spontaneous chronic colitis, which can be detected using P- and E-selectin-targeted ultrasound molecular imaging (USMI) starting at 6 weeks of age without substantial difference between male and female mice or between the locations of the colon

  • The result showed a prominent correlation between USMI findings and ex vivo histology and immunofluorescence staining

Read more

Summary

Introduction

Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract.IBD comprises two distinct phenotypes: Crohn’s disease (CD), and ulcerative colitis (UC).The prevalence of IBD has been increasing during past decades, from developed to developing countries, especially in pediatric patients [1,2]. Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract. IBD comprises two distinct phenotypes: Crohn’s disease (CD), and ulcerative colitis (UC). Nanomaterials 2022, 12, 280 inflammatory disorder with relapsing-remission cycles. The diagnosis of IBD mainly relies on clinical symptoms and signs, along with laboratory and imaging findings. Such clinical findings are not parallel to the disease activity of IBD [4,5], and they fail to provide clear indications for “go or no go” treatments, likely leading to either under- or over-treatments. Non-invasive, accurate, and quantitative tools are crucial for the multiple follow-up exams of IBD patients to monitor the disease activity and to determine treatment regimens

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.